UK ITP Treatment Update: Quentin Hill on Generic Eltrombopag Access and Guidance
Quentin Hill, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust, has shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag.
Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licensed treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar, and greater use of generic eltrombopag will result in a substantial, multi-million-pound cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP.
However, patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
You can find more information here.
Find more posts on Hemostasis Today.
-
Aug 22, 2026, 17:27Masudah Paleker: Suboptimal Warfarin Control in South Africa
-
Aug 22, 2026, 17:26Maxime Dely: Sickle Cell Disease – Behind Every Exchange, There Is a Donor
-
Aug 22, 2026, 17:05Mostafa Elshazly: Managing Anticoagulant-Related Bleeding in Clinical Practice
-
Aug 22, 2026, 17:01Cesarovic Nikola: FDA Data Reanalysis Raises Questions About Moderna’s mFLUSIVA Risk-Benefit Profile
-
Aug 22, 2026, 16:38Andreas Linkermann: Decoding the Chain Reaction of Ferroptotic Cell Death
-
Aug 22, 2026, 16:33Nicolas Hulscher: FDA Data Reanalysis Raises Alarms Over Moderna’s MFLUSIVA
-
Aug 22, 2026, 16:19Moti Haim: Transforming AF Care in the Elderly
-
Aug 22, 2026, 16:12Hussam Hammoud: A Slap Is Not “Just a Slap” When the Patient Has Hemophilia
-
Aug 22, 2026, 15:53Howard Smith: Publix’s GreenWise Organic Frozen Berries Have E. coli Contamination